Cancer: important reason for poor response to checkpoint inhibitors identified. The aim of immunotherapies is to enable the immune system once again to fight cancer on its own. Drugs known as checkpoint inhibitors are already in clinical use for this purpose. However, they are only effective in about one third of patients. Based on analysis
Source NIH Director’s Blog Exercise can work wonders for your health, including strengthening muscles and bones, and boosting metabolism, mood, and memory skills. Now comes word that staying active may also help to lower your odds of developing cancer. After reviewing the scientific evidence, a panel of experts recently concluded that physical activity is associated with reduced
Cancer cells are masters at avoiding detection, but a new system developed by Yale scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, the researchers report Oct. 14 in the journal Nature Immunology. The new system reduced or eliminated
Source: H. Lee Cancer Center & Research Institute Patients with advanced melanoma have been able to live longer because of several newly approved targeted treatment options, including BRAF and MEK inhibitors. However, patients will often have different responses to the same treatment due to genetic variability. Melanoma varies from patient to patient, but genetic variability is
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the retina) as early as week 16 and at one year
Novel immunotherapy extends therapy now used in fighting leukemia, Tel Aviv University researchers say There is now a multitude of therapies to treat cancer, from chemotherapy and radiation to immunotherapy and small molecule inhibitors. Chemotherapy is still the most widely used cancer treatment, but chemotherapy attacks all the rapidly dividing cells that it locates within
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
The FDA has granted duvelisib (Copiktra) with an orphan drug designation for the treatment of patients with T-cell lymphoma, according to a press release from Verastem Oncology, the company developing duvelisib.1 The PI3K-δ,γ inhibitor demonstrated efficacy in a phase I study and is currently being investigated in the phase II PRIMO trial (NCT03372057). “Receiving orphan
Source Cancer Network Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care. Some of these new treatments are detailed below. LOXO-292 Various multikinase inhibitors (MKI) with some activity against RET have
